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 ABSTRACT 
 Objective Despite the wide use of anti-M ü llerian hormone (AMH) measurement as a clinical marker for 
assessment of ovarian reserve, a population-based estimate for its reference values is not available. In this 
study, we have estimated age-specifi c AMH levels in a large sample of fertile women directly selected from a 
general population cohort. 
 Methods All women who were naturally fertile and aged 18 – 50 years with regular menstrual cycles were 
selected from the Tehran Lipid and Glucose Study cohort and their blood levels of AMH were measured. 
Centiles for AMH distribution were estimated according to the exponential – normal 3-parameter model. We 
repeated the analysis after including a subgroup of women aged 40 – 50 years who met all the eligibility cri-
teria except having entered natural menopause after age 40 years ( n    141). 
 Results A total of 1015 women entered the study. The mean age was 36.7 years (standard deviation 
7.5 years) and the mean body mass index was 27.0 kg/m 2 (standard deviation 4.6 kg/m 2 ). A non-linear decline 
of serum AMH concentration with age was observed. Age-specifi c AMH levels for the 5th, 10th, 25th, 50th, 
75th, 90th and 95th percentiles were calculated. Results were reproduced after inclusion of 141 women aged 
40 – 50 years who met all the eligibility criteria except having entered natural menopause after 40 years. 
 Conclusion In this study, we have presented a nomogram of age-specifi c estimates of anti-M ü llerian hormone 
in a large sample of naturally fertile women within the general population. This could help clinicians in more 
accurate individual interpretation of serum AMH levels in healthy women. 
 INTRODUCTION 
 There is growing body of research suggesting anti-M ü llerian 
hormone (AMH) as the best biomarker for determining 
ovarian reserve or prediction of age at menopause 1 – 4 , as 
it accurately refl ects the gradual age-related decline of 
reproductive capacity 5 – 7 . Several nomograms for AMH 
have been published 1,8 – 18 , of which only a small number 
were in fertile women 1,8,9,13,16,17 . All existing literature used 
hospital-based samples which may not be suitable for 
the general population. Few studies had access to large 
samples and some were restricted by lack of a uniform, 
widely acceptable laboratory measurement kit for AMH, 
resulting in use of unreliable conversion factors within a 
single study 1,13 . 
 In this study, we have estimated age-specifi c AMH levels 
in a large sample of fertile women directly selected from a 
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 MATERIALS AND METHODS 
 We used data from the Tehran Lipid and Glucose Study 
(TLGS). This is an ongoing, prospective, general population 
cohort from a geographically defi ned population of a district 
in Tehran initiated in 1998 to assess the prevalence and risk 
factors of non-communicable diseases. A total number of 
15 005 people were selected through multistage cluster sam-
pling and enrolled in the cohort after signing a written 
informed consent 19 . Subjects were physically examined and 
their demographic and reproductive characteristics as well as 
blood samples were collected. Blood samples were taken from 
the participants between 07.00 and 09.00 after 12 h overnight 
fasting. Samples were centrifuged within 30 – 45 min of collec-
tion and stored at -80 ° C. Questions about reproductive his-
tory included marital status, regularity of menstrual cycle, 
parity, history of infertility, and current and previous use of 
contraceptive methods. 
 We examined all women aged 18 – 50 years who were par-
ticipants in the TLGS and selected those who met our eligi-
bility criteria ( n    1015), which included having regular and 
predictable menstrual cycles at the initiation of the study, 
having proven natural fertility (at least one term pregnancy 
within 1 year after stopping contraception), and no history 
of endocrine disorders, hysterectomy, oophorectomy or any 
other kind of ovarian surgery. All eligible women had discon-
tinued hormonal contraception for at least 3 months before 
entering the study. We excluded those with incomplete data or 
those for whom blood samples were not available. 
 The serum concentration of AMH at the time of recruit-
ment was measured by the two-site enzyme immunoassay 
(EIA) method using the Gen II kit (Beckman Coulter, Inc., 
CA, USA) and the Sunrise ELISA reader (Tecan Co., Salzburg, 
Austria). All AMH measurements were performed simultane-
ously at the same laboratory. AMH Gen II controls A79766 
were used at two levels of concentration to monitor accuracy 
of assay. The intra- and inter-assay coeffi cients of variation 
were 1.9% and 2.0%, respectively. 
 Statistical analysis 
 The relationship between AMH levels and the characteristics 
of the study subjects such as body mass index (BMI) and parity 
were explored using pair-wise Spearman’s correlation and par-
tial correlation coeffi cients. The normal-based methodology 
described in Altman and Chitty 20 , and Royston and Wright 21 , 
 Table 1 Characteristics of the study population ( n    1015). Data are 
given as mean (standard deviation) 
Age (years) 36.7 (7.5)
Parity 3.1 (1.6)
Abortion 0.4 (0.7)
Body mass index (kg/m 2 ) 27.0 (4.6)
Waist circumferences (cm) 85.3 (11.1)
Hip circumference (cm) 104.1 (8.8)
Systolic blood pressure (mmHg) 111.1 (13.4)
Diastolic blood pressure (mmHg) 74.8 (9.5)
Anti-M ü llerian hormone (ng/ml)
20 – 30 years 3.5 (2.3)
31 – 40 years 1.7 (1.4)
41 – 50 years 0.6 (0.8)
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 DISCUSSION 
 Our study reports age-specifi c serum AMH levels for a large 
sample of naturally fertile women that to the best of our 
knowledge for the fi rst time were taken directly from a general 
population cohort. 
 Several nomograms for AMH have been published 1,9 – 18 
so far, but the majority of these nomograms are based on 
measurements performed in infertile women 10 – 12,14,15,18 . 
The results from these studies could not be generalized to 
a normal population as their ovarian aging is highly infl u-
enced by their associated conditions such as polycystic ovary 
was used to estimate age-specifi c AMH percentiles. Fractional 
polynomial (FP) regression models were fi tted separately to 
estimate the mean and standard deviation (SD) of the log 
AMH values as functions of age. The SD was modeled using 
the scaled absolute residuals from the estimated regression 
model for the mean. An FP of fi rst degree with power 2 and 
a second-degree FP with powers (3, 3) were selected for mean 
and SD, respectively. The percentiles were obtained by combin-
ing these two regression models, using the assumption that the 
conditional distribution of log AMH values given age is nor-
mal. Percentile curves on the original scales (AMH nomogram) 
were obtained by taking the antilog of the calculated curves. 
 The normal plot of the  Z -scores from the normal model 
described above showed that normality does not hold ( p value 
for the Shapiro – Wilk test    0.001). An exponential – normal 
(EN) 3-parameter model 22 provided a much improved fi t, with 
a deviance 66.47 lower than the normal model ( p    0.001). 
The normal plot of the  Z -scores from the EN model appears 
reasonably linear ( p value for the Shapiro – Wilk test    0.16), 
and 9.8% of the observations lie above the 90th percentile and 
9.1% below the 10th percentile. The EN model was fi tted by 
maximum likelihood using the STATA command xriml 23,24 . 
 We repeated the analysis after including a subgroup of 
women aged 40 – 50 who met all the eligibility criteria except 
having entered natural menopause after age 40 years ( n    141). 
The date of their last cycle was recorded and an arbitrary 
value of 0.1 ng/ml was assumed as the serum concentration 
of AMH at that time. All statistical analyses were performed 
using STATA version 11 (Statacorp, TX, USA). 
 RESULTS 
 The demographic and reproductive characteristics of study 
participants are presented in Table 1. The mean age of the 
women was 36.7 years (SD    7.5 years) and the mean BMI 
was 27.0 kg/m 2 (SD    4.6 kg/m 2 ) with 34.3% and 40.9% of 
women having BMI values    25 kg/m 2 and 25 – 29 kg/m 2 , 
respectively; 24.8% were categorized as obese with BMI 
values    30 kg/m 2 . The mean AMH level was 1.65 ng/ml 
(SD    1.81 ng/ml). 
 The correlation coeffi cient between AMH and BMI was 
 r     0.15 ( p    0.001). After adjustment for age, it changed to 
 r    0.075 ( p    0.016). There was a signifi cant negative corre-
lation between AMH levels and parity ( r     0.39;  p    0.001) 
and it became statistically non-signifi cant after adjustment 
for age. 
 Figure 1 shows AMH values as a function of age and the 
estimated values of AMH for the 5th, 10th, 25th, 50th, 75th, 
90th and 95th centiles in 1015 study participants, resulting 
from the EN model. The age-specifi c AMH values and their 
corresponding percentiles have been summarized in Table 2. 
Figure 2 and Table 3 show the AMH and age nomogram 
and their corresponding values after including the 141 meno-
pausal women aged 40 – 50 ( n    1156). The results show a 
reduction in the 95th percentile cut-off value of AMH for 
women aged more than 40 years. 
 Table 2 Age-specifi c values of anti-M ü llerian hormone and 




 5th  10th  25th  50th  75th  90th  95th 
18 2.66 3.22 4.24 5.51 6.91 8.27 9.13
19 2.33 2.87 3.89 5.18 6.64 8.10 9.03
20 2.02 2.54 3.54 4.85 6.37 7.91 8.92
21 1.74 2.24 3.21 4.53 6.09 7.72 8.79
22 1.50 1.96 2.91 4.21 5.81 7.51 8.65
23 1.28 1.71 2.62 3.91 5.53 7.29 8.49
24 1.09 1.49 2.35 3.61 5.24 7.06 8.31
25 0.92 1.29 2.10 3.33 4.96 6.81 8.11
26 0.78 1.11 1.87 3.05 4.67 6.55 7.89
27 0.66 0.96 1.66 2.79 4.38 6.28 7.65
28 0.55 0.82 1.47 2.55 4.10 5.99 7.38
29 0.46 0.70 1.30 2.32 3.82 5.70 7.10
30 0.39 0.60 1.14 2.10 3.55 5.39 6.79
31 0.32 0.51 1.00 1.89 3.28 5.08 6.46
32 0.27 0.44 0.88 1.70 3.02 4.75 6.11
33 0.23 0.37 0.77 1.53 2.76 4.43 5.74
34 0.19 0.32 0.67 1.37 2.52 4.10 5.36
35 0.16 0.27 0.59 1.22 2.28 3.77 4.97
36 0.13 0.23 0.51 1.08 2.06 3.44 4.57
37 0.11 0.20 0.45 0.95 1.85 3.12 4.17
38 0.10 0.17 0.39 0.84 1.65 2.81 3.78
39 0.08 0.15 0.34 0.74 1.46 2.51 3.39
40 0.07 0.13 0.29 0.65 1.29 2.22 3.01
41 0.06 0.11 0.26 0.57 1.13 1.95 2.64
42 0.05 0.10 0.22 0.49 0.98 1.70 2.30
43 0.05 0.08 0.19 0.43 0.85 1.46 1.97
44 0.04 0.07 0.17 0.37 0.73 1.25 1.68
45 0.04 0.07 0.15 0.32 0.62 1.05 1.41
46 0.03 0.06 0.13 0.27 0.52 0.88 1.17
47 0.03 0.05 0.11 0.23 0.44 0.72 0.95
48 0.03 0.05 0.10 0.20 0.36 0.59 0.77
49 0.03 0.04 0.09 0.17 0.30 0.47 0.61
50 0.03 0.04 0.08 0.14 0.25 0.38 0.48
51 0.02 0.04 0.07 0.12 0.20 0.29 0.37
52 0.02 0.04 0.06 0.10 0.16 0.23 0.28
53 0.02 0.03 0.05 0.09 0.13 0.17 0.21
54 0.02 0.03 0.05 0.07 0.10 0.13 0.15
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the  Z -scores from our model appears reasonably linear and 
about 10% of the observations lie above the 90th percentile 
and about 10% below the 10th percentile. 
 We believe that reaching menopause after age 40 years is 
considered a physiologic reproductive event 29 – 31 , while in 
our original sample ( n    1015) we had excluded all women 
who had entered menopause regardless of their age. The 
cross-section of women who had entered our study in this 
way did not therefore fully refl ect the study population. As 
they reached older age, more women with longer reproduc-
tive life spans remained in our sample and the representative-
ness of the sample further deteriorated. In other words, not 
all healthy fertile women aged 40 – 50 had an equal chance 
of participating in the sample. To overcome this problem, we 
included women who had reached menopause after 40 years 
of age given that they met other eligibility criteria ( n    141). 
However, as we could not measure their AMH level at the 
time of menopause, an arbitrary value of 0.1 ng/ml, based 
on literature 32 , was assigned to them; this we believe pro-
vided estimates of AMH percentiles that better refl ect the 
true AMH range in the general population of women. We 
observed a downward shift in the percentile curves, as we 
expected, providing more realistic values of AMH particu-
larly for the older age groups in our study population. 
 We found that AMH levels and BMI were negatively cor-
related, which is similar to the fi ndings of other studies 9,33 – 35 
and may be partly explained by the fact that aging women 
tend to have a higher BMI. Adjustment for age changed the 
correlation coeffi cient between AMH and BMI from  r    0.15 
( p    0.001) to  r    0.075 ( p    0.016) which supports the above 
assertion. We found no signifi cant relationship between the 
number of pregnancies and AMH levels after adjustment for 
syndrome 25 , endometriosis 26 and ovarian surgeries 27 . There 
are a few hospital-based studies reporting AMH nomograms 
for healthy women 1,8,9,13,17 . However, they may not fully rep-
resent the general population and all except one of them did 
not have access to a large sample; this large study was con-
ducted among 1298 Korean women visiting hospitals but the 
reasons for their visits have not been reported 13 . Furthermore, 
AMH nomograms were obtained via a mixture of various 
AMH lab kits 1 and unreliable conversion factors 28 may not be 
suffi ciently reliable. The current study, however, uses a large 
sample of healthy fertile women from the community to make 
the AMH nomogram. 
 Compared to the available estimates for age-specifi c AMH 
levels for healthy fertile women 8 , our results have fewer 
fl uctuations. This could be due to its large sample size 
(having adequate numbers of women in various age groups) 
and clear eligibility criterion of  ‘ proven fertility ’ . Our AMH 
estimates are somewhat lower than those reported by studies 
without  ‘ proven fertility ’ as one of their essential inclusion 
criteria 9,13 . This could be because their results may have 
been infl uenced by the AMH levels of those with hidden 
fertility problems. 
 Several statistical models have been introduced to present 
the relationship between age and AMH. In agreement with 
most data available 1,8,11,15 , our study shows a non-linear 
AMH decline with age. Several non-linear models have been 
presented and their suitability assessed by taking into account 
their goodness of fi t ( r 2 values) as well as their simplicity. 
The quadratic model was found to be the most appropriate 
model by many researchers, given its comparable  r 2 values and 
ease of interpretation 8,11,15 . However, we found that the EN 
3-parameter model provided a decent fi t; the normal plot of 
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been shown that European and Iranian women share age at 
natural menopause-associated genetic variants 41 . Therefore, 
we believe that the estimates we have provided are reasonably 
applicable to all women. 
 There are suggestions that AMH may be unstable under 
some storage or assay conditions, particularly when the 
Gen II kit 42 is used for assays. We believe this is not a 
problem in our study considering that blood samples taken 
as part of the TLGS study were centrifuged within 30 – 45 
min of collection and stored at   80 ° C. The amount of 
intra-assay variability in our data is likely to be minimal 
because all the laboratory measurements were performed 
simultaneously at the same laboratory by the same person. 
Another challenge is the interpretation of values obtained 
by various AMH kits 28 . Despite an excellent correlation 
between the new Gen II kit and both the Diagnostic Systems 
Lab (DSL) and Immunotech (IOT) systems 43,44 , however, 
there is no universal conversion factor for converting val-
ues obtained by the Gen II kit to the other two mentioned. 
Therefore we do not recommend adapting our age-specifi c 
AMH cut-offs based on the Gen II assay to older ones by 
direct conversion. 
 In this study, we have presented a nomogram of age-
specifi c estimates of anti-M ü llerian hormone in a large 
sample of naturally fertile women within the general popula-
tion. This could help clinicians in more accurate individual 
interpretation of serum anti-M ü llerian hormone levels in 
healthy women. 
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 Table 3 Age-specifi c values of anti-M ü llerian hormone and 




 5th  10th  25th  50th  75th  90th  95th 
18 2.43 2.95 3.97 5.31 6.88 8.51 9.59
19 2.11 2.62 3.62 4.98 6.62 8.35 9.51
20 1.83 2.31 3.29 4.65 6.35 8.18 9.42
21 1.58 2.03 2.98 4.34 6.07 7.99 9.31
22 1.35 1.77 2.68 4.03 5.79 7.78 9.19
23 1.15 1.54 2.41 3.72 5.50 7.56 9.04
24 0.98 1.34 2.15 3.43 5.21 7.33 8.86
25 0.83 1.16 1.92 3.15 4.92 7.07 8.66
26 0.70 1.00 1.70 2.89 4.63 6.80 8.43
27 0.59 0.86 1.51 2.64 4.34 6.51 8.17
28 0.50 0.73 1.33 2.40 4.05 6.20 7.88
29 0.42 0.63 1.17 2.17 3.76 5.88 7.56
30 0.35 0.54 1.03 1.96 3.48 5.55 7.21
31 0.29 0.46 0.91 1.76 3.20 5.20 6.83
32 0.25 0.39 0.79 1.58 2.93 4.85 6.43
33 0.21 0.34 0.69 1.41 2.67 4.49 6.00
34 0.18 0.29 0.61 1.26 2.42 4.12 5.56
35 0.15 0.25 0.53 1.12 2.18 3.76 5.10
36 0.13 0.21 0.46 0.99 1.95 3.40 4.64
37 0.11 0.18 0.40 0.87 1.74 3.05 4.18
38 0.09 0.16 0.35 0.77 1.54 2.71 3.73
39 0.08 0.14 0.31 0.67 1.35 2.39 3.29
40 0.07 0.12 0.27 0.58 1.18 2.08 2.86
41 0.06 0.11 0.23 0.51 1.02 1.79 2.46
42 0.06 0.09 0.20 0.44 0.87 1.53 2.09
43 0.05 0.08 0.18 0.38 0.74 1.29 1.75
44 0.05 0.07 0.16 0.33 0.63 1.07 1.45
45 0.04 0.07 0.14 0.28 0.53 0.88 1.18
46 0.04 0.06 0.12 0.24 0.44 0.72 0.94
47 0.04 0.06 0.11 0.20 0.36 0.57 0.74
48 0.04 0.05 0.10 0.17 0.29 0.45 0.57
49 0.03 0.05 0.09 0.15 0.24 0.35 0.44
50 0.03 0.05 0.08 0.12 0.19 0.27 0.33
51 0.03 0.05 0.07 0.10 0.15 0.20 0.24
52 0.04 0.04 0.06 0.09 0.12 0.15 0.17
53 0.04 0.04 0.06 0.07 0.09 0.11 0.12
54 0.04 0.04 0.05 0.06 0.07 0.08 0.08
55 0.04 0.04 0.05 0.05 0.05 0.05 0.06
age. Therefore, as shown by other studies 9,36 , it seems that 
reproductive outcomes of fertile women are not related to 
their individual age-specifi c AMH levels. 
 This is the fi rst study reporting an AMH nomogram 
among a general Iranian population. There is some research 
suggesting that ovarian aging or AMH levels may be infl u-
enced by race and ethnicity 37,38 and disparity in reproductive 
aging among Asian subpopulations has been reported 39 . How-
ever, the results of the Study of Women ’ s Health Across the 
Nations (SWAN) demonstrated no difference in menopausal 
age among various racial/ethnic groups after controlling for 
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